Clinical issues in long-term treatment with antidepressants

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 2, 2000, Pages 20-25

  Zajecka, John M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; BETHANECHOL; BROMOCRIPTINE MESILATE; BUSPIRONE; CYPROHEPTADINE; DEXAMPHETAMINE; ESTROGEN; FAMOTIDINE; FLUOXETINE; GINKGO BILOBA EXTRACT; GRANISETRON; METHYLPHENIDATE; MIRTAZAPINE; NEFAZODONE; NEOSTIGMINE; PAROXETINE; PEMOLINE; PEMOLINE MAGNESIUM; SILDENAFIL; TOPIRAMATE; TRAZODONE; VENLAFAXINE; YOHIMBINE; ZALEPLON; ZOLPIDEM TARTRATE;

CONFERENCE PAPER; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SOMNOLENCE;

ANTIDEPRESSIVE AGENTS; ASTHENIA; ATTITUDE TO HEALTH; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; EATING DISORDERS; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION; RECURRENCE; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; WEIGHT GAIN;

EID: 0034009877     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Keller MB, Lavori PW, Lewis CE, et al. Predictors of relapse in major depressive disorder. JAMA 1983;250:3299-3304
2. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-816
3. Frank E, Kupfer DJ, Parel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099
4. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995;4:261-277
5. Keller MB, Klerman GL, Lavori PW, et al. Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 1984;252:788-792
6. Keller MB. Depression: underrecognition and undertreatment by psychiatrists and other health care professionals. Arch Intern Med 1990;150: 946-948
7. Rush AJ, Thase ME. Strategies and tactics in the treatment of chronic depression. J Clin Psychiatry 1997;58(suppl 13):14-22
8. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency foi Health Care Policy and Research: 1993. AHCPR publication 93-0551
9. Rush AJ, Hollon S, Beck AT, et al. Depression: must pharmacotherapy fail for cognitive therapy to succeed? Cognitive Ther Res 1978;2:199-206
10. Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response: a critical review. Arch Gen Psychiatry 1976;33:1479-1489
11. Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatment. J Clin Psychiatry 1998; 59:279-288
12. Fawcett J. Antidepressants: partial response in chronic depression. Br J Psychiatry 1994:26(suppl):37-41
13. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995;4:261-277
14. Katon W, von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992;30:67-76
15. Perel JM. Compliance during tricyclic antidepressant therapy: pharmaco-kinetic and analytical issues. Clin Chemistry 1988;34:881-887
16. Lin EH, von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressani therapy. Med Care 1995;33:67-74
17. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997;58:291-297
18. Zajecka JM, Miles W, Cobb T, et al. The safety of abrupt discontinuation of nefazodone. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association: June 4, 1998; Toronto, Ontario, Canada. Abstract NR716:262
19. Croft H, Settle E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999;21:643-657
20. Delgado PI, McGahuey CA, Moreno FA, et al. Treatment strategies for depression and sexual dysfunction. J Clin Psychiatry Monograph 1999;17 (1):15-21
21. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62
22. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85
23. Fava M, Rankin MA, Albert JE. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction. Psychother Psychosom 1998;67: 328-331
24. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dys-function: efficacy of a drug holiday. Am J Psychiatry 1995;152:1514-1516